Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT05524324

Cardiac Resynchronization Therapy in Adult Congenital Heart Disease With Systemic Right Ventricle: RIGHT-CRT

Led by Assistance Publique - Hôpitaux de Paris · Updated on 2024-07-11

40

Participants Needed

13

Research Sites

182 weeks

Total Duration

On this page

Sponsors

A

Assistance Publique - Hôpitaux de Paris

Lead Sponsor

M

Ministry of Health, France

Collaborating Sponsor

AI-Summary

What this Trial Is About

The main objective of RIGHT-CRT is to assess the impact/efficacy of CRT on functional capacity in ACHD patients with SRV.

CONDITIONS

Official Title

Cardiac Resynchronization Therapy in Adult Congenital Heart Disease With Systemic Right Ventricle: RIGHT-CRT

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Systemic right ventricle (SRV)
  • CRT-P or CRT-D device implanted for at least 1 month
  • Age 18 years or older
  • One of the two following CRT indications:
    • NYHA class II-IV, right ventricular ejection fraction 35% or less, and spontaneous QRS duration 150 ms or more
    • NYHA class I-IV, atrioventricular conduction disorders with ventricular pacing over 40%, regardless of right ventricular ejection fraction
  • Affiliation to a French social security system (beneficiary or legal)
  • Informed and signed consent
Not Eligible

You will not qualify if you...

  • Pregnancy or breastfeeding
  • Women of childbearing potential without negative pregnancy test and without use of hormonal contraception, intrauterine device, or bilateral tubal occlusion
  • Patient under legal protection measures (guardianship, curatorship, judicial safeguard, activated future protection mandate, family authorization)
  • Cardiac surgery in the last 3 months or planned in the next 6 months
  • Percutaneous structural cardiac intervention planned in the next 6 months
  • Persistent atrial arrhythmia with catheter ablation planned in the next 6 months
  • Acute congestive heart failure
  • Dysfunction of at least one CRT device lead affecting biventricular pacing
  • Patient receiving AME
  • Current participation in another interventional clinical study or in an exclusion period after a previous study

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 13 locations

1

CHU de Caen

Caen, France

Actively Recruiting

2

Hôpital Marie-Lannelongue

Le Plessis-Robinson, France

Actively Recruiting

3

CHU de Lille

Lille, France

Not Yet Recruiting

4

Hôpital Louis Pradel

Lyon, France

Actively Recruiting

5

Hôpital La Timone

Marseille, France

Actively Recruiting

6

CHU de Montpellier

Montpellier, France

Actively Recruiting

7

CHU de Nantes

Nantes, France

Actively Recruiting

8

Ap-Hp Hegp

Paris, France, 75015

Actively Recruiting

9

AP-HP, Pitié-Salpétrière

Paris, France

Actively Recruiting

10

CHU de Rouen

Rouen, France

Actively Recruiting

11

CHU de Toulouse

Toulouse, France

Not Yet Recruiting

12

Clinique Pasteur

Toulouse, France

Not Yet Recruiting

13

CHU de Tours

Tours, France

Actively Recruiting

Loading map...

Research Team

K

Karine Goude

CONTACT

L

Laura Le Mao

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

CROSSOVER

Primary Purpose

OTHER

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here